Teneobio, Inc.   Report issue

For profit Phase 1
Founded: Newark CA United States (2009)
Status: Acquired by Amgen (2021)

Organization Overview

First Clinical Trial
2019
NCT03933735
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Teneobio, Inc. | TeneoOne Inc. | TeneoTwo Inc.